In parallel, hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitors, such as daprodustat and vadadustat, correct CKD-related anemia by stabilizing HIF-α, thereby increasing endogenous erythropoietin and lowering hepcidin to improve functional iron deficiency. This evidence concerns the gene EPO and Iron deficiency anemia.